

# CONTENTS

<b>PREFACE</b>	xv
<b>ACKNOWLEDGMENTS</b>	xix
<b>ABOUT THE AUTHOR</b>	xxi
<b>SYMBOLS USED IN THIS BOOK</b>	xxiii
<b>BOOK ABSTRACT</b>	xxix
<b>1 Introduction</b>	<b>1</b>
1.1 A Difficult Problem, 1	
1.2 An Expensive Problem, 2	
1.3 Where Computational Techniques are Used, 3	
Bibliography, 5	
<b>PART I THE DRUG DESIGN PROCESS</b>	<b>7</b>
<b>2 Properties that Make a Molecule a Good Drug</b>	<b>9</b>
2.1 Compound Testing, 10	
2.1.1 Biochemical Assays, 11	
2.1.2 Cell-Based Assays, 13	

- 2.1.3 Animal Testing, 14
- 2.1.4 Human Clinical Trials, 15
- 2.2 Molecular Structure, 16
  - 2.2.1 Activity, 16
  - 2.2.2 Bioavailability and Toxicity, 24
  - 2.2.3 Drug Side Effects, 26
  - 2.2.4 Multiple Drug Interactions, 26
- 2.3 Metrics for Drug-Likeness, 27
- 2.4 Exceptions to the Rules, 33
- Bibliography, 35

### **3 Target Identification 41**

- 3.1 Primary Sequence and Metabolic Pathway, 41
- 3.2 Crystallography, 43
- 3.3 2D NMR, 44
- 3.4 Homology Models, 45
- 3.5 Protein Folding, 45
- Bibliography, 46

### **4 Target Characterization 47**

- 4.1 Analysis of Target Mechanism, 47
  - 4.1.1 Kinetics and Crystallography, 48
  - 4.1.2 Automated Crevice Detection, 48
  - 4.1.3 Transition Structures and Reaction Coordinates, 49
  - 4.1.4 Molecular Dynamics Simulations, 49
- 4.2 Where the Target is Expressed, 50
- 4.3 Pharmacophore Identification, 50
- 4.4 Choosing an Inhibitor Mechanism, 51
- Bibliography, 52

### **5 The Drug Design Process for a Known Protein Target 53**

- 5.1 The Structure-Based Design Process, 53
- 5.2 Initial Hits, 55
- 5.3 Compound Refinement, 56
- 5.4 ADMET, 67
- 5.5 Drug Resistance, 67
- Bibliography, 68

<b>6</b>	<b>The Drug Design Process for an Unknown Target</b>	<b>71</b>
6.1	The Ligand-Based Design Process, 71	
6.2	Initial Hits, 72	
6.3	Compound Refinement, 73	
6.4	ADMET, 74	
	Bibliography, 74	

<b>7</b>	<b>Drug Design for Other Targets</b>	<b>75</b>
7.1	DNA Binding, 76	
7.2	RNA as a Target, 78	
7.3	Allosteric Sites, 79	
7.4	Receptor Targets, 80	
7.5	Steroids, 81	
7.6	Targets inside Cells, 82	
7.7	Targets within the Central Nervous System, 83	
7.8	Irreversibly Binding Inhibitors, 84	
7.9	Upregulating Target Activity, 84	
	Bibliography, 85	

<b>8</b>	<b>Compound Library Design</b>	<b>87</b>
8.1	Targeted Libraries versus Diverse Libraries, 87	
8.2	From Fragments versus from Reactions, 89	
8.3	Non-Enumerative Techniques, 90	
8.4	Drug-Likeness and Synthetic Accessibility, 91	
8.5	Analyzing Chemical Diversity and Spanning known Chemistries, 93	
8.6	Compound Selection Techniques, 96	
	Bibliography, 99	

## **PART II COMPUTATIONAL TOOLS AND TECHNIQUES** **103**

<b>9</b>	<b>Homology Model Building</b>	<b>105</b>
9.1	How much Similarity is Enough?, 106	
9.2	Steps for Building a Homology Model, 107	
9.2.1	Step 1: Template Identification, 108	
9.2.2	Step 2: Alignment between the Unknown and the Template, 108	

9.2.3	Step 3: Manual Adjustments to the Alignment, 110	
9.2.4	Step 4: Replace Template Side Chains with Model Side Chains, 111	
9.2.5	Step 5: Adjust Model for Insertions and Deletions, 111	
9.2.6	Step 6: Optimization of the Model, 112	
9.2.7	Step 7: Model Validation, 112	
9.2.8	Step 8: If Errors are Found, Iterate Back to Previous Steps, 115	
9.3	Reliability of Results, 116	
	Bibliography, 117	
<b>10</b>	<b>Molecular Mechanics</b>	<b>119</b>
10.1	A Really Brief Introduction to Molecular Mechanics, 119	
10.2	Force Fields for Drug Design, 121	
	Bibliography, 123	
<b>11</b>	<b>Protein Folding</b>	<b>125</b>
11.1	The Difficulty of the Problem, 125	
11.2	Algorithms, 127	
11.3	Reliability of Results, 129	
11.4	Conformational Analysis, 130	
	Bibliography, 131	
<b>12</b>	<b>Docking</b>	<b>133</b>
12.1	Introduction, 133	
12.2	Search Algorithms, 135	
12.2.1	Searching the Entire Space, 135	
12.2.2	Grid Potentials versus Full Force Field, 137	
12.2.3	Flexible Active Sites, 138	
12.2.4	Ligands Covalently Bound to the Active Site, 138	
12.2.5	Hierarchical Docking Algorithms, 139	
12.3	Scoring, 141	
12.3.1	Energy Expressions and Consensus Scoring, 141	
12.3.2	Binding Free Energies, 141	
12.3.3	Solvation, 144	
12.3.4	Ligands Covalently Bound to the Active Site, 144	
12.3.5	Metrics for Goodness of Fit, 144	
12.4	Validation of Results, 145	
12.5	Comparison of Existing Search and Scoring Methods, 146	
12.6	Special Systems, 153	

12.7	The Docking Process, 155	
12.7.1	Protein Preparation, 156	
12.7.2	Building the Ligand, 156	
12.7.3	Setting the Bounding Box, 157	
12.7.4	Docking Options, 157	
12.7.5	Running the Docking Calculation, 158	
12.7.6	Analysis of Results, 158	
	Bibliography, 159	
<b>13</b>	<b>Pharmacophore Models</b>	<b>161</b>
13.1	Components of a Pharmacophore Model, 163	
13.2	Creating a Pharmacophore Model from Active Compounds, 164	
13.3	Creating a Pharmacophore Model from the Active Site, 166	
13.4	Searching Compound Databases, 167	
13.5	Reliability of Results, 168	
	Bibliography, 169	
<b>14</b>	<b>QSAR</b>	<b>171</b>
14.1	Conventional QSAR versus 3D-QSAR, 171	
14.2	The QSAR Process, 172	
14.3	Descriptors, 175	
14.4	Automated QSAR Programs, 176	
14.5	QSAR versus Other Fitting Methods, 177	
	Bibliography, 178	
<b>15</b>	<b>3D-QSAR</b>	<b>181</b>
15.1	The 3D-QSAR Process, 182	
15.2	3D-QSAR Software Packages, 184	
15.3	Summary, 184	
	Bibliography, 184	
<b>16</b>	<b>Quantum Mechanics in Drug Design</b>	<b>187</b>
16.1	Quantum Mechanics Algorithms and Software, 188	
16.2	Modeling Systems with Metal Atoms, 191	
16.3	Increased Accuracy, 191	
16.4	Computing Reaction Paths, 193	
16.5	Computing Spectra, 193	
	Bibliography, 194	

<b>17</b>	<b><i>De novo</i> and Other AI Techniques</b>	<b>197</b>
17.1	<i>De novo</i> Building of Compounds, 198	
17.2	Nonquantitative Predictions, 201	
17.3	Quantitative Predictions, 203	
	Bibliography, 205	
<b>18</b>	<b>Cheminformatics</b>	<b>207</b>
18.1	Smiles, SLN, and Other Chemical Structure Representations, 208	
18.2	Similarity and Substructure Searching, 209	
18.3	2D-to-3D Structure Generation, 213	
18.4	Clustering Algorithms, 214	
18.5	Screening Results Analysis, 217	
18.6	Database Systems, 222	
	Bibliography, 223	
<b>19</b>	<b>ADMET</b>	<b>225</b>
19.1	Oral Bioavailability, 227	
19.2	Drug Half-Life in the Bloodstream, 229	
19.3	Blood–Brain Barrier Permeability, 231	
19.4	Toxicity, 231	
	Bibliography, 234	
<b>20</b>	<b>Multiobjective Optimization</b>	<b>237</b>
	Bibliography, 240	
<b>21</b>	<b>Automation of Tasks</b>	<b>241</b>
21.1	Built-In Automation Capabilities, 241	
21.2	Automation Using External Utilities, 243	
	Bibliography, 244	
<b>PART III RELATED TOPICS</b>		<b>245</b>
<b>22</b>	<b>Bioinformatics</b>	<b>247</b>
	Bibliography, 251	

<b>23 Simulations at the Cellular and Organ Level</b>	<b>253</b>
23.1 Cellular Simulations, 253	
23.2 Organ Simulations, 256	
Bibliography, 256	
<b>24 Synthesis Route Prediction</b>	<b>259</b>
Bibliography, 262	
<b>25 Proteomics</b>	<b>263</b>
Bibliography, 264	
<b>26 Prodrug Approaches</b>	<b>267</b>
Bibliography, 270	
<b>27 Future Developments in Drug Design</b>	<b>273</b>
27.1 Individual Patient Genome Sequencing, 273	
27.2 Analysis of the Entire Proteome, 274	
27.3 Drugs Customized for Ethnic Group or Individual Patient, 274	
27.4 Genetic Manipulation, 275	
27.5 Cloning, 276	
27.6 Stem Cells, 277	
27.7 Longevity, 278	
Bibliography, 279	
<b>Appendix: About the CD</b>	<b>281</b>
<b>GLOSSARY</b>	<b>285</b>
<b>INDEX</b>	<b>301</b>